Cargando…
DAB2IP attenuates chemoresistance of triple‐negative breast cancer through sequestration of RAC1 to prevent β‐catenin nuclear accumulation
BACKGROUND: Although chemotherapy, the most widely used systemic treatment in triple‐negative breast cancer (TNBC), markedly improved the patients’ outcome, chemoresistance always occurs. This study purposed to explore new therapeutic strategies for the treatment of chemoresistance. METHODS AND RESU...
Autores principales: | Xiong, Zhenchong, Yang, Lin, Li, Ning, Fu, Jianchang, Liu, Peng, Sun, Peng, Wei, Weidong, Xie, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763535/ https://www.ncbi.nlm.nih.gov/pubmed/36536485 http://dx.doi.org/10.1002/ctm2.1133 |
Ejemplares similares
-
DAB2IP in cancer
por: Liu, Liang, et al.
Publicado: (2015) -
Loss of DAB2IP Contributes to Cell Proliferation and Cisplatin Resistance in Gastric Cancer
por: Wang, Guannan, et al.
Publicado: (2021) -
TUFT1 Promotes Triple Negative Breast Cancer Metastasis, Stemness, and Chemoresistance by Up-Regulating the Rac1/β-Catenin Pathway
por: Liu, Weiguang, et al.
Publicado: (2019) -
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour
por: Dote, H, et al.
Publicado: (2005) -
Association of a sequence variant in DAB2IP with coronary heart disease
por: Harrison, Seamus C., et al.
Publicado: (2012)